

October 11, 2011
Seikagaku Corporation
Straumann Japan K.K.

Announcement of the Transfer of Emdogain Gel[®], a Medical Device Used in Dentistry

Tokyo, Japan, October 11, 2011—Seikagaku Corporation (hereafter “Seikagaku”) (head office: Chiyoda-ku, Tokyo) and Straumann Japan K.K. (hereafter “Straumann Japan”) (head office: Chiyoda-ku, Tokyo) today announced that they have agreed on the transfer to Straumann Japan of the role of Designated Marketing Approval Holder*¹ for Emdogain Gel^{®*2}, a medical device used in dentistry, accompanying the expiration on December 31, 2011 of Seikagaku’s exclusive sales agreement in Japan with Institut Straumann AG (head office: Basel, Switzerland).

Emdogain Gel[®] has been manufactured by Biora AB (head office: Malmö, Sweden), imported and marketed in Japan by Seikagaku in its role as Designated Marketing Approval Holder, and sold in the market through Yoshida Dental Trade Distribution Co., Ltd. (hereafter “Yoshida”) (head office: Taito-ku, Tokyo), a dental equipment general trading company. Under the agreement, from January 2012 Straumann Japan will commence the importation and sale of Emdogain Gel[®], and Yoshida will remain the distributor.

In accordance with the “Seikagaku Corporation Ten-Year Vision”, Seikagaku will further specialize in core businesses, centered on pharmaceuticals, with the aim of continued business development as a “Global Category Pharma” focused on research and development with the emphasis on glycoscience.

Straumann Japan aims to provide a more broad-based total solution in the field of dentistry by adding to its product line Emdogain Gel[®], a product used to induce regeneration of periodontium.

The impact of the transfer of Emdogain Gel[®] on Seikagaku's forecast of consolidated results for the fiscal year ending March 31, 2012 (announced in May 2011) will be minor.

Background Information

**1 Designated Marketing Approval Holder*

A Designated Marketing Approval Holder is a licensed marketing approval holder designated by a foreign manufacturer when it has obtained approval to register a medical device in Japan under the Foreign Restrictive Approval System. A Designated Marketing Approval Holder, which must have obtained a medical device and/or pharmaceuticals marketing license, is contracted to perform work relating to GQP (Good Quality Practice) and GVP (Good Vigilance Practice).

**2 Emdogain Gel[®]*

Emdogain Gel[®] (Specially Controlled Medical Device: approval number 21300BZG00049000) is a medical device used in dentistry developed by focusing on a structural protein that plays an important role during the period of tooth development. At the time of periodontal surgery for the treatment of periodontitis, application of Emdogain Gel[®] to the root surface has the effect of inducing regeneration of periodontium to its normal structure and function. Biora AB obtained manufacturing approval for Emdogain Gel[®] as a foreign-made medical device on December 11, 2001, and Seikagaku has imported and marketed the product since March 2002.

#####